{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=9", "query": { "intervention": "TMZ", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 469, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T05:17:50.326Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01107522", "title": "Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas" ], "interventions": [ { "name": "CTO", "type": "DRUG" }, { "name": "CTO and Temodar®", "type": "DRUG" }, { "name": "CTO, Temodar®, Radiation therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tactical Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2010-05", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-19T05:17:50.326Z", "location_count": 4, "location_summary": "New York, New York • Portland, Oregon", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01107522" }, { "nct_id": "NCT05236036", "title": "Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Astrocytoma", "Glioblastoma", "Glioblastoma, IDH-Wildtype", "MGMT-Unmethylated Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2022-08-08", "completion_date": "2029-01-03", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-19T05:17:50.326Z", "location_count": 3, "location_summary": "Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" }, { "city": "Warrenville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05236036" }, { "nct_id": "NCT03323034", "title": "Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 30, "start_date": "2018-01-11", "completion_date": "2024-09-30", "has_results": true, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-10-19T05:17:50.326Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03323034" }, { "nct_id": "NCT04796012", "title": "VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "6 Months to 30 Years" }, "enrollment_count": 23, "start_date": "2023-04-18", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-19T05:17:50.326Z", "location_count": 7, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Cincinnati, Ohio + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04796012" }, { "nct_id": "NCT01977677", "title": "Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Ependymoblastoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Medulloblastoma", "Adult Mixed Glioma", "Adult Oligodendroglial Tumors", "Adult Pineoblastoma", "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)" ], "interventions": [ { "name": "radiation therapy", "type": "RADIATION" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "plerixafor", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER" ], "sponsor": "Lawrence Recht", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2014-11", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2018-10-23", "last_synced_at": "2026-10-19T05:17:50.326Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01977677" }, { "nct_id": "NCT01113957", "title": "A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "ABT-888", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 168, "start_date": "2010-03", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-10-19T05:17:50.326Z", "location_count": 15, "location_summary": "Duarte, California • Encino, California • Los Angeles, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01113957" }, { "nct_id": "NCT02315534", "title": "A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "BBI608", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2015-03", "completion_date": "2019-06-24", "has_results": true, "last_update_posted_date": "2023-11-15", "last_synced_at": "2026-10-19T05:17:50.326Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315534" }, { "nct_id": "NCT00302159", "title": "Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Gliomas", "Brain Tumors" ], "interventions": [ { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 43, "start_date": "2006-03", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-08-18", "last_synced_at": "2026-10-19T05:17:50.326Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania • Richmond, Virginia", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00302159" }, { "nct_id": "NCT00612989", "title": "Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Temodar and O6-Benzylguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2005-02", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2014-07-16", "last_synced_at": "2026-10-19T05:17:50.326Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612989" }, { "nct_id": "NCT07859059", "title": "Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Glioma", "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Dexbrompheniramine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 41, "start_date": "2027-06-01", "completion_date": "2031-06-01", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-19T05:17:50.326Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07859059" } ] }